FierceBiotech4h
Boehringer widens fibrosis drug’s approval path after boosting lung function in 2nd phase 3 trial
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in a related lung disease leading the drugmaker to expand the indications it ...
Hosted on MSN5h
The 10 Leading Causes Of Death In America
In the United States, the annual death rate is at over three million. Knowing the top ten diseases responsible for U.S.
pharmaphorum5h
Pliant slumps on decision to pause lung disease drug trial
Shares in Pliant Therapeutics plunged in after-hours trading after the US biotech revealed that it has paused a phase 2b/3 trial of its lead drug for idiopathic pulmonary fibrosis (IPF) after seeing a ...
manilatimes6h
Boehringer's nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis
FIBRONEER™-ILD was a double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nerandomilast ...
Healio6h
Odds for injurious fall heightened with fall-risk increasing drug prescription in COPD
The adjusted likelihood for an injurious fall in adults with COPD was elevated with a fall-risk increasing drug prescription, ...
Everything to know about cystic fibrosis and what causes it
The genetic disorder cystic fibrosis is unique because it can cause both breathing and digestive problems. Some 40,000 people in the U.S. currently have it, "though this is likely an underestimate as ...
Air pollution is affecting more than just the lungs
No matter what causes air pollution, it continues to increase throughout the United States, with over 131 million people ...